| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SRRA | Common Stock | Disposed to Issuer | -$550K | -10K | -100% | $55.00 | 0 | Jul 1, 2022 | Direct | |
| transaction | SRRA | Common Stock | Disposed to Issuer | -$275K | -5K | -100% | $55.00 | 0 | Jul 1, 2022 | By spouse |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SRRA | Stock Option (right to buy | Disposed to Issuer | $0 | -11.7K | -100% | $0.00* | 0 | Jul 1, 2022 | Common Stock | 11.7K | $268.20 | Direct | F1, F2 |
| transaction | SRRA | Stock Option (right to buy) | Disposed to Issuer | $0 | -2.06K | -100% | $0.00* | 0 | Jul 1, 2022 | Common Stock | 2.06K | $263.20 | Direct | F2, F3 |
| transaction | SRRA | Stock Option (right to buy) | Disposed to Issuer | $0 | -11.4K | -100% | $0.00* | 0 | Jul 1, 2022 | Common Stock | 11.4K | $72.80 | Direct | F2, F4 |
| transaction | SRRA | Stock Option (right to buy) | Disposed to Issuer | $0 | -1.75K | -100% | $0.00* | 0 | Jul 1, 2022 | Common Stock | 1.75K | $58.00 | Direct | F2, F5 |
| transaction | SRRA | Stock Option (right to buy) | Disposed to Issuer | $0 | -4.51K | -100% | $0.00* | 0 | Jul 1, 2022 | Common Stock | 4.51K | $94.40 | Direct | F2, F6 |
| transaction | SRRA | Stock Option (right to buy) | Disposed to Issuer | $0 | -5K | -100% | $0.00* | 0 | Jul 1, 2022 | Common Stock | 5K | $78.40 | Direct | F2, F7 |
| transaction | SRRA | Stock Option (right to buy) | Disposed to Issuer | $0 | -167K | -100% | $0.00* | 0 | Jul 1, 2022 | Common Stock | 167K | $13.31 | Direct | F8, F9 |
| transaction | SRRA | Stock Option (right to buy) | Disposed to Issuer | $0 | -49K | -100% | $0.00* | 0 | Jul 1, 2022 | Common Stock | 49K | $12.15 | Direct | F9, F10 |
| transaction | SRRA | Stock Option (right to buy) | Disposed to Issuer | $0 | -30K | -100% | $0.00* | 0 | Jul 1, 2022 | Common Stock | 30K | $16.73 | Direct | F9, F11 |
| transaction | SRRA | Stock Option (right to buy) | Disposed to Issuer | $0 | -50K | -100% | $0.00* | 0 | Jul 1, 2022 | Common Stock | 50K | $31.54 | Direct | F9, F12 |
Barbara Klencke is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | The option fully vested on June 11, 2019. |
| F2 | Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. |
| F3 | The option fully vested on January 1, 2020. |
| F4 | The option fully vested on September 30, 2019. |
| F5 | The option fully vested on January 1, 2021. |
| F6 | The option fully vested on January 1, 2022. |
| F7 | The option vested as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. |
| F8 | The option vested as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
| F9 | Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. |
| F10 | On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. |
| F11 | The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date. |
| F12 | The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date. |